The DOI matches its Crossref record; 405 of the 405 references it cites were found in a registry or an index.
Targeting Cyclin-Dependent Kinases in Human Cancers: From Small Molecules to Peptide Inhibitors
Open accessAbstract
Cyclin-dependent kinases (CDK/Cyclins) form a family of heterodimeric kinases that play central roles in regulation of cell cycle progression, transcription and other major biological processes including neuronal differentiation and metabolism. Constitutive or deregulated hyperactivity of these kinases due to amplification, overexpression or mutation of cyclins or CDK, contributes to proliferation of cancer cells, and aberrant activity of these kinases has been reported in a wide variety of human cancers. These kinases therefore constitute biomarkers of proliferation and attractive pharmacological targets for development of anticancer therapeutics. The structural features of several of these kinases have been elucidated and their molecular mechanisms of regulation characterized in depth, providing clues for development of drugs and inhibitors to disrupt their function. However, like most other kinases, they constitute a challenging class of therapeutic targets due to their highly conserved structural features and ATP-binding pocket. Notwithstanding, several classes of inhibitors have been discovered from natural sources, and small molecule derivatives have been synthesized through rational, structure-guided approaches or identified in high throughput screens. The larger part of these inhibitors target ATP pockets, but a growing number of peptides targeting protein/protein interfaces are being proposed, and a small number of compounds targeting allosteric sites have been reported.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Prevention of Chemotherapy-Induced Alopecia in Rats by CDK Inhibitors
Davis, S. T., Benson, B. G., Bramson, H. N., Chapman, D. E., Dickerson, S. H., Dold, K. M., Eberwein, D. J., Edelstein, M., Frye, S. V., Gampe, R. T., et al. (2001) · Science · doi:10.1126/science.291.5501.134 · Cited by 166
RetractedHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Meijer, L., Nelson, D. J., Riazanski, V., Gabdoulkhakova, A. G., Hery-Arnaud, G., Le Berre, R., Loaëc, N., Oumata, N., Galons, H., Nowak, E., et al. (2016) · Journal of Innate Immunity · doi:10.1159/000444256 · Cited by 4,992
The retinoblastoma protein and cell cycle control
Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90385-2 · Cited by 4,862
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957
Morgan, D. O. (1995) · Nature · doi:10.1038/374131a0 · Cited by 3,284
A census of human cancer genes
Futreal, P. A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N., & Stratton, M. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1299 · Cited by 3,184
Patterns of somatic mutation in human cancer genomes
Greenman, C., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G., Davies, H., Teague, J., Butler, A., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,080
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
Staurosporine, a potent inhibitor of phospholipidCa++dependent protein kinase
Tamaoki, T., Nomoto, H., Takahashi, I., Kato, Y., Morimoto, M., & Tomita, F. (1986) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(86)90008-2 · Cited by 2,452
CYCLIN-DEPENDENT KINASES: Engines, Clocks, and Microprocessors
Morgan, D. O. (1997) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.13.1.261 · Cited by 2,259
The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer
Vermeulen, K., Van Bockstaele, D. R., & Berneman, Z. N. (2003) · Cell Proliferation · doi:10.1046/j.1365-2184.2003.00266.x · Cited by 1,773
Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
Arkin, M. R., & Wells, J. A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1343 · Cited by 1,705
Hartwell, L. H., Culotti, J., Pringle, J. R., & Reid, B. J. (1974) · Science · doi:10.1126/science.183.4120.46 · Cited by 1,567
Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration
Patrick, G. N., Zukerberg, L., Nikolic, M., de la Monte, S., Dikkes, P., & Tsai, L.-H. (1999) · Nature · doi:10.1038/45159 · Cited by 1,545
Evans, T., Rosenthal, E. T., Youngblom, J., Distel, D., & Hunt, T. (1983) · Cell · doi:10.1016/0092-8674(83)90420-8 · Cited by 1,516
Cdks, cyclins and CKIs: roles beyond cell cycle regulation
Lim, S., & Kaldis, P. (2013) · Development · doi:10.1242/dev.091744 · Cited by 1,487
To cycle or not to cycle: a critical decision in cancer
Malumbres, M., & Barbacid, M. (2001) · Nature Reviews Cancer · doi:10.1038/35106065 · Cited by 1,468
Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex
Jeffrey, P. D., Russo, A. A., Polyak, K., Gibbs, E., Hurwitz, J., Massagué, J., & Pavletich, N. P. (1995) · Nature · doi:10.1038/376313a0 · Cited by 1,436
Cyclin D as a therapeutic target in cancer
Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3090 · Cited by 1,370
Mammalian cyclin-dependent kinases
Malumbres, M., & Barbacid, M. (2005) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2005.09.005 · Cited by 1,295
Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236
Giacinti, C., & Giordano, A. (2006) · Oncogene · doi:10.1038/sj.onc.1209615 · Cited by 1,216
A p16 INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma
Wölfel, T., Hauer, M., Schneider, J., Serrano, M., Wölfel, C., Klehmann-Hieb, E., De Plaen, E., Hankeln, T., Meyer zum Büschenfelde, K.-H., & Beach, D. (1995) · Science · doi:10.1126/science.7652577 · Cited by 1,154
CDK inhibitors: Cell cycle regulators and beyond
Besson, A., Dowdy, S. F., & Roberts, J. M. (2008) · Developmental Cell · doi:10.1016/j.devcel.2008.01.013 · Cited by 1,152
Complementation used to clone a human homologue of the fission yeast cell cycle control gene cdc2
Lee, M. G., & Nurse, P. (1987) · Nature · doi:10.1038/327031a0 · Cited by 1,140
Cdk1 is sufficient to drive the mammalian cell cycle
Santamaría, D., Barrière, C., Cerqueira, A., Hunt, S., Tardy, C., Newton, K., Cáceres, J. F., Dubus, P., Malumbres, M., & Barbacid, M. (2007) · Nature · doi:10.1038/nature06046 · Cited by 1,114
Rational design of inhibitors that bind to inactive kinase conformations
Liu, Y., & Gray, N. S. (2006) · Nature Chemical Biology · doi:10.1038/nchembio799 · Cited by 1,094
Living with or without cyclins and cyclin-dependent kinases
Sherr, C. J., & Roberts, J. M. (2004) · Genes & Development · doi:10.1101/gad.1256504 · Cited by 1,089
Neurotoxicity induces cleavage of p35 to p25 by calpain
Lee, M.-S., Kwon, Y. T., Li, M., Peng, J., Friedlander, R. M., & Tsai, L.-H. (2000) · Nature · doi:10.1038/35012636 · Cited by 1,063
Dhavan, R., & Tsai, L.-H. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35096019 · Cited by 1,058
Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment
Shapiro, G. I. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.7689 · Cited by 1,036
Crystal structure of cyclin-dependent kinase 2
De Bondt, H. L., Rosenblatt, J., Jancarik, J., Jones, H. D., Morgan, D. O., & Kim, S.-H. (1993) · Nature · doi:10.1038/363595a0 · Cited by 976
NEW EMBO MEMBER'S REVIEW: Diversity of protein-protein interactions
Nooren, I. M. A. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg359 · Cited by 932
A family of human cdc2-related protein kinases.
Meyerson, M., Enders, G. H., Wu, C. L., Su, L. K., Gorka, C., Nelson, C., Harlow, E., & Tsai, L. H. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05360.x · Cited by 923
p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5
Tsai, L.-H., Delalle, I., Caviness, V. S., Chae, T., & Harlow, E. (1994) · Nature · doi:10.1038/371419a0 · Cited by 922
Crystal structure of the p27Kip1 cyclin-dependent-kinase inibitor bound to the cyclin A–Cdk2 complex
Russo, A. A., Jeffrey, P. D., Patten, A. K., Massagué, J., & Pavletich, N. P. (1996) · Nature · doi:10.1038/382325a0 · Cited by 907
Cell cycle kinases as therapeutic targets for cancer
Lapenna, S., & Giordano, A. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2907 · Cited by 905
Genetic control of cell size at cell division in yeast
Nurse, P. (1975) · Nature · doi:10.1038/256547a0 · Cited by 861
Alonso, A. D. C., Zaidi, T., Novak, M., Grundke-Iqbal, I., & Iqbal, K. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.121119298 · Cited by 827
Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma
Zuo, L., Weger, J., Yang, Q., Goldstein, A. M., Tucker, M. A., Walker, G. J., Hayward, N., & Dracopoli, N. C. (1996) · Nature Genetics · doi:10.1038/ng0196-97 · Cited by 818
Hoessel, R., Leclerc, S., Endicott, J. A., Nobel, M. E. M., Lawrie, A., Tunnah, P., Leost, M., Damiens, E., Marie, D., Marko, D., et al. (1999) · Nature Cell Biology · doi:10.1038/9035 · Cited by 809
Exploiting Chemical Libraries, Structure, and Genomics in the Search for Kinase Inhibitors
Gray, N. S., Wodicka, L., Thunnissen, A.-M. W. H., Norman, T. C., Kwon, S., Espinoza, F. H., Morgan, D. O., Barnes, G., LeClerc, S., Meijer, L., et al. (1998) · Science · doi:10.1126/science.281.5376.533 · Cited by 808
Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1
Vassilev, L. T., Tovar, C., Chen, S., Knezevic, D., Zhao, X., Sun, H., Heimbrook, D. C., & Chen, L. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600447103 · Cited by 796
Cyclin D-dependent kinases, INK4 inhibitors and cancer
Ortega, S., Malumbres, M., & Barbacid, M. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(02)00037-9 · Cited by 778
Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms
Satyanarayana, A., & Kaldis, P. (2009) · Oncogene · doi:10.1038/onc.2009.170 · Cited by 774
Molecular mechanisms of neurodegeneration in Alzheimer's disease
Crews, L., & Masliah, E. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq160 · Cited by 772
Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer
(1996) · Advances in cancer research · doi:10.1016/s0065-230x(08)60352-8 · Cited by 752
Gillett, C., Fantl, V., Smith, D., Fisher, C., Bartek, J. J., Dickson, C., Barnes, D. M., & Peters, G. (1994) · PubMed · Cited by 750
De Azevedo, W. F., Leclerc, S., Meijer, L., Havlicek, L., Strnad, M., & Kim, S. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.0518a.x · Cited by 729
Inhibition of α-helix-mediated protein–protein interactions using designed molecules
Azzarito, V., Long, K., Murphy, N. S., & Wilson, A. J. (2013) · Nature Chemistry · doi:10.1038/nchem.1568 · Cited by 727
Leclerc, S., Garnier, M., Hoessel, R., Marko, D., Bibb, J. A., Snyder, G. L., Greengard, P., Biernat, J., Wu, Y.-Z., Mandelkow, E.-M., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m002466200 · Cited by 723
Inactivation of the p34 cdc2 -Cyclin B Complex by the Human WEE1 Tyrosine Kinase
Parker, L. L., & Piwnica-Worms, H. (1992) · Science · doi:10.1126/science.1384126 · Cited by 716
Targeting the cancer kinome through polypharmacology
Knight, Z. A., Lin, H., & Shokat, K. M. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2787 · Cited by 674
CDK8 is a colorectal cancer oncogene that regulates β-catenin activity
Firestein, R., Bass, A. J., Kim, S. Y., Dunn, I. F., Silver, S. J., Guney, I., Freed, E., Ligon, A. H., Vena, N., Ogino, S., et al. (2008) · Nature · doi:10.1038/nature07179 · Cited by 672
Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma
Wang, J., Chenivesse, X., Henglein, B., & Bréchot, C. (1990) · Nature · doi:10.1038/343555a0 · Cited by 671
Common markers of proliferation
Whitfield, M. L., George, L. K., Grant, G. D., & Perou, C. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1802 · Cited by 650
Purification of maturation-promoting factor, an intracellular regulator of early mitotic events.
Lohka, M. J., Hayes, M. K., & Maller, J. L. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.9.3009 · Cited by 644
Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15.
Gu, Y., Rosenblatt, J., & Morgan, D. O. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05493.x · Cited by 642
Inhibition of Cyclin‐Dependent Kinases by Purine Analogues
Veselý, J., Havliček, L., Strnad, M., Blow, J. J., Donella‐Deana, A., Pinna, L., Letham, D. S., Kato, J., Detivaud, L., Leclerc, S., et al. (1994) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1994.00771.x · Cited by 632
Active cyclin B1–Cdk1 first appears on centrosomes in prophase
Jackman, M., Lindon, C., Nigg, E. A., & Pines, J. (2003) · Nature Cell Biology · doi:10.1038/ncb918 · Cited by 612
Cruz, J. C., Tseng, H.-C., Goldman, J. A., Shih, H., & Tsai, L.-H. (2003) · Neuron · doi:10.1016/s0896-6273(03)00627-5 · Cited by 609
Structural basis of cyclin-dependent kinase activation by phosphorylation
Russo, A. A., Jeffrey, P. D., & Pavletich, N. P. (1996) · Nature Structural & Molecular Biology · doi:10.1038/nsb0896-696 · Cited by 598
The cdk5/p35 kinase is essential for neurite outgrowth during neuronal differentiation.
Nikolic, M., Dudek, H., Kwon, Y. T., Ramos, Y. F., & Tsai, L. H. (1996) · Genes & Development · doi:10.1101/gad.10.7.816 · Cited by 598
A brain-specific activator of cyclin-dependent kinase 5
Lew, J., Huang, Q.-Q., Qi, Z., Winkfein, R. J., Aebersold, R., Hunt, T., & Wang, J. H. (1994) · Nature · doi:10.1038/371423a0 · Cited by 579
Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
Parry, D., Guzi, T., Shanahan, F., Davis, N., Prabhavalkar, D., Wiswell, D., Seghezzi, W., Paruch, K., Dwyer, M. P., Doll, R., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0324 · Cited by 558
Molecular Pathogenesis and a Consequent Classification of Multiple Myeloma
Bergsagel, P. L., & Kuehl, W. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.021 · Cited by 556
Pharmacological inhibitors of cyclin-dependent kinases
Knockaert, M., Greengard, P., & Meijer, L. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)02071-0 · Cited by 537
Blazek, D., Kohoutek, J., Bartholomeeusen, K., Johansen, E., Hulinkova, P., Luo, Z., Cimermancic, P., Ule, J., & Peterlin, B. M. (2011) · Genes & Development · doi:10.1101/gad.16962311 · Cited by 522
Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6
Toogood, P. L., Harvey, P. J., Repine, J. T., Sheehan, D. J., VanderWel, S. N., Zhou, H., Keller, P. R., McNamara, D. J., Sherry, D., Zhu, T., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049354h · Cited by 513
Malignant melanoma: genetics and therapeutics in the genomic era
Chin, L., Garraway, L. A., & Fisher, D. E. (2006) · Genes & Development · doi:10.1101/gad.1437206 · Cited by 511
CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas.
Schmidt, E., Ichimura, K., Reifenberger, G., & Collins, V. P. (1994) · PubMed · Cited by 508
De Azevedo, W. F., Mueller-Dieckmann, H. J., Schulze-Gahmen, U., Worland, P. J., Sausville, E., & Kim, S. H. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.7.2735 · Cited by 496
Melanoma: from mutations to medicine
Tsao, H., Chin, L., Garraway, L. A., & Fisher, D. E. (2012) · Genes & Development · doi:10.1101/gad.191999.112 · Cited by 496
Preclinical and Clinical Development of Cyclin-Dependent Kinase Modulators
Senderowicz, A. M. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.5.376 · Cited by 492
A census of amplified and overexpressed human cancer genes
Santarius, T., Shipley, J., Brewer, D., Stratton, M. R., & Cooper, C. S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2771 · Cited by 482
Abnormal Alzheimer‐like phosphorylation of tau‐protein by cyclin‐dependent kinases cdk2 and cdk5
Baumann, K., Mandelkow, E.-M., Biernat, J., Piwnica-Worms, H., & Mandelkow, E. (1993) · FEBS Letters · doi:10.1016/0014-5793(93)80849-p · Cited by 478
Substrates for p34cdc2: In vivo veritas?
Moreno, S., & Nurse, P. (1990) · Cell · doi:10.1016/0092-8674(90)90463-o · Cited by 474
Activity and expression pattern of cyclin-dependent kinase 5 in the embryonic mouse nervous system
Tsai, L.-H., Takahashi, T., Caviness, V. S., & Harlow, E. (1993) · Development · doi:10.1242/dev.119.4.1029 · Cited by 457
CDK targets Sae2 to control DNA-end resection and homologous recombination
Huertas, P., Cortés-Ledesma, F., Sartori, A. A., Aguilera, A., & Jackson, S. P. (2008) · Nature · doi:10.1038/nature07215 · Cited by 456
Flavopiridol Inhibits P-TEFb and Blocks HIV-1 Replication
Chao, S.-H., Fujinaga, K., Marion, J. E., Taube, R., Sausville, E. A., Senderowicz, A. M., Peterlin, B. M., & Price, D. H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000446200 · Cited by 455
Meijer, L., Thunnissen, A.-M., White, A., Garnier, M., Nikolic, M., Tsai, L.-H., Walter, J., Cleverley, K., Salinas, P., Wu, Y.-Z., et al. (2000) · Chemistry & Biology · doi:10.1016/s1074-5521(00)00063-6 · Cited by 454
Phosphorylation of mammalian CDC6 by Cyclin A/CDK2 regulates its subcellular localization
Petersen, B. O. (1999) · The EMBO Journal · doi:10.1093/emboj/18.2.396 · Cited by 430
Puyol, M., Martín, A., Dubus, P., Mulero, F., Pizcueta, P., Khan, G., Guerra, C., Santamaría, D., & Barbacid, M. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.025 · Cited by 415
Coleman, T. R., & Dunphy, W. G. (1994) · Current Opinion in Cell Biology · doi:10.1016/0955-0674(94)90060-4 · Cited by 414
The when and wheres of CDC25 phosphatases
Boutros, R., Dozier, C., & Ducommun, B. (2006) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2006.02.003 · Cited by 414
Nuclear cyclin D1: an oncogenic driver in human cancer
Kim, J. K., & Diehl, J. A. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21791 · Cited by 413
CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1
Bartkowiak, B., Liu, P., Phatnani, H. P., Fuda, N. J., Cooper, J. J., Price, D. H., Adelman, K., Lis, J. T., & Greenleaf, A. L. (2010) · Genes & Development · doi:10.1101/gad.1968210 · Cited by 400
Alternate splicing produces a novel cyclin D1 transcript.
Betticher, D., Thatcher, N., Altermatt, H. J., Hoban, P. R., Ryder, W. D. J., & Heighway, J. (1995) · PubMed · Cited by 399
Kaneko, S., Li, G., Son, J., Xu, C.-F., Margueron, R., Neubert, T. A., & Reinberg, D. (2010) · Genes & Development · doi:10.1101/gad.1983810 · Cited by 398
Regulation of cyclin-Cdk activity in mammalian cells
Obaya, A. J., & Sedivy, J. M. (2002) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s00018-002-8410-1 · Cited by 397
The histone variant macroH2A suppresses melanoma progression through regulation of CDK8
Kapoor, A., Goldberg, M. S., Cumberland, L. K., Ratnakumar, K., Segura, M. F., Emanuel, P. O., Menendez, S., Vardabasso, C., LeRoy, G., Vidal, C. I., et al. (2010) · Nature · doi:10.1038/nature09590 · Cited by 397
Driving the cell cycle with a minimal CDK control network
Coudreuse, D., & Nurse, P. (2010) · Nature · doi:10.1038/nature09543 · Cited by 396
TFIIH is negatively regulated by cdk8-containing mediator complexes
Akoulitchev, S., Chuikov, S., & Reinberg, D. (2000) · Nature · doi:10.1038/35024111 · Cited by 393
Wei, Y., Chen, Y.-H., Li, L.-Y., Lang, J., Yeh, S.-P., Shi, B., Yang, C.-C., Yang, J.-Y., Lin, C.-Y., Lai, C.-C., et al. (2011) · Nature Cell Biology · doi:10.1038/ncb2139 · Cited by 384
Calpain-dependent Proteolytic Cleavage of the p35 Cyclin-dependent Kinase 5 Activator to p25
Kusakawa, G.-I., Saito, T., Onuki, R., Ishiguro, K., Kishimoto, T., & Hisanaga, S.-I. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m907757199 · Cited by 381
Kinase Drug Discovery – What’s Next in the Field?
Cohen, P., & Alessi, D. R. (2013) · ACS Chemical Biology · doi:10.1021/cb300610s · Cited by 377
Binding of small molecules to an adaptive protein–protein interface
Arkin, M. R., Randal, M., DeLano, W. L., Hyde, J., Luong, T. N., Oslob, J. D., Raphael, D. R., Taylor, L., Wang, J., McDowell, R. S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.252756299 · Cited by 375
Adams, P. D., Sellers, W. R., Sharma, S. K., Wu, A. D., Nalin, C. M., & Kaelin, W. G. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.12.6623 · Cited by 373
Substrate recruitment to cyclin-dependent kinase 2 by a multipurpose docking site on cyclin A
Schulman, B. A., Lindstrom, D. L., & Harlow, E. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.18.10453 · Cited by 372
Lam, L. T., Pickeral, O. K., Peng, A. C., Rosenwald, A., Hurt, E. M., Giltnane, J. M., Averett, L. M., Zhao, H., Davis, R. E., Sathyamoorthy, M., et al. (2001) · Genome Biology · doi:10.1186/gb-2001-2-10-research0041 · Cited by 370
Cyclin D1: polymorphism, aberrant splicing and cancer risk
Knudsen, K. E., Diehl, J. A., Haiman, C. A., & Knudsen, E. S. (2006) · Oncogene · doi:10.1038/sj.onc.1209371 · Cited by 363
Secrets of a double agent: CDK7 in cell-cycle control and transcription
Fisher, R. P. (2005) · Journal of Cell Science · doi:10.1242/jcs.02718 · Cited by 363
Labbe, J. C., Picard, A., Peaucellier, G., Cavadore, J. C., Nurse, P., & Doree, M. (1989) · Cell · doi:10.1016/0092-8674(89)90963-x · Cited by 361
Roscovitine Targets, Protein Kinases and Pyridoxal Kinase
Bach, S., Knockaert, M., Reinhardt, J., Lozach, O., Schmitt, S., Baratte, B., Koken, M., Coburn, S. P., Tang, L., Jiang, T., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500806200 · Cited by 356
Potent Inhibition of Cdc2 Kinase Activity by the Flavonoid L86-8275
Losiewicz, M. D., Carlson, B. A., Kaur, G., Sausville, E. A., & Worland, P. J. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.1742 · Cited by 345
Wyatt, P. G., Woodhead, A. J., Berdini, V., Boulstridge, J. A., Carr, M. G., Cross, D. M., Davis, D. J., Devine, L. A., Early, T. R., Feltell, R. E., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800382h · Cited by 340
Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC
Goga, A., Yang, D., Tward, A. D., Morgan, D. O., & Bishop, J. M. (2007) · Nature Medicine · doi:10.1038/nm1606 · Cited by 326
Smith, P. D., Crocker, S. J., Jackson-Lewis, V., Jordan-Sciutto, K. L., Hayley, S., Mount, M. P., O'Hare, M. J., Callaghan, S., Slack, R. S., Przedborski, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2232515100 · Cited by 319
Cyclin C/Cdk3 Promotes Rb-Dependent G0 Exit
Ren, S., & Rollins, B. J. (2004) · Cell · doi:10.1016/s0092-8674(04)00300-9 · Cited by 316
Labbe, J. C., Lee, M. G., Nurse, P., Picard, A., & Doree, M. (1988) · Nature · doi:10.1038/335251a0 · Cited by 308
Cyclin-Dependent Kinases in Brain Development and Disease
Su, S. C., & Tsai, L.-H. (2011) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-092910-154023 · Cited by 303
Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication.
Soria, J., Jang, S. J., Khuri, F. R., Hassan, K. A., Liu, D., Hong, W. K., & Mao, L. (2000) · PubMed · Cited by 299
Cyclin B2-null mice develop normally and are fertile whereas cyclin B1-null mice die in utero
Brandeis, M., Rosewell, I., Carrington, M., Crompton, T., Jacobs, M. A., Kirk, J., Gannon, J., & Hunt, T. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4344 · Cited by 291
Paudel, H. K., Lew, J., Ali, Z., & Wang, J. H. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)49492-1 · Cited by 285
Dei Tos, A. P., Doglioni, C., Piccinin, S., Sciot, R., Furlanetto, A., Boiocchi, M., Dal Cin, P., Maestro, R., Fletcher, C. D. M., & Tallini, G. (2000) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(200004)190:5<531::aid-path579>3.0.co;2-w · Cited by 285
Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2
Chen, S., Bohrer, L. R., Rai, A. N., Pan, Y., Gan, L., Zhou, X., Bagchi, A., Simon, J. A., & Huang, H. (2010) · Nature Cell Biology · doi:10.1038/ncb2116 · Cited by 281
Structure and Regulation of the CDK5-p25nck5a Complex
Tarricone, C., Dhavan, R., Peng, J., Areces, L. B., Tsai, L.-H., & Musacchio, A. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00343-4 · Cited by 280
Delayed early embryonic lethality following disruption of the murine cyclin A2 gene
Murphy, M., Stinnakre, M.-G., Senamaud-Beaufort, C., Winston, N. J., Sweeney, C., Kubelka, M., Carrington, M., Bréchot, C., & Sobczak-Thépot, J. (1997) · Nature Genetics · doi:10.1038/ng0197-83 · Cited by 279
Neuronal cdc2-like kinase: a cdc2-related protein kinase with predominantly neuronal expression.
Hellmich, M. R., Pant, H. C., Wada, E., & Battey, J. F. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.22.10867 · Cited by 278
Chesi, M., Bergsagel, P., Brents, L., Smith, C., Gerhard, D., & Kuehl, W. (1996) · Blood · doi:10.1182/blood.v88.2.674.bloodjournal882674 · Cited by 277
Warbrick, E., Lane, D. P., Glover, D. M., & Cox, L. S. (1995) · Current Biology · doi:10.1016/s0960-9822(95)00058-3 · Cited by 277
Cell Cycle Control of Wnt Receptor Activation
Davidson, G., Shen, J., Huang, Y.-L., Su, Y., Karaulanov, E., Bartscherer, K., Hassler, C., Stannek, P., Boutros, M., & Niehrs, C. (2009) · Developmental Cell · doi:10.1016/j.devcel.2009.11.006 · Cited by 275
Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy
Sedlacek, H., Czech, J., Naik, R., Kaur, G., Worland, P., Losiewicz, M., Parker, B., Carlson, B., Smith, A., Senderowicz, A., et al. (1996) · International Journal of Oncology · doi:10.3892/ijo.9.6.1143 · Cited by 275
From Cdc2 to Cdk1: when did the cell cycle kinase join its cyclin partner?
Dorée, M., & Hunt, T. (2002) · Journal of Cell Science · doi:10.1242/jcs.115.12.2461 · Cited by 274
Chang, Y.-T., Gray, N. S., Rosania, G. R., Sutherlin, D. P., Kwon, S., Norman, T. C., Sarohia, R., Leost, M., Meijer, L., & Schultz, P. G. (1999) · Chemistry & Biology · doi:10.1016/s1074-5521(99)80048-9 · Cited by 268
The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma
Sheppard, K. E., & McArthur, G. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0259 · Cited by 265
Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis.
Gansauge, S., Gansauge, F., Ramadani, M., Stobbe, H., Rau, B., Harada, N., & Beger, H. G. (1997) · PubMed · Cited by 261
Wiestner, A., Tehrani, M., Chiorazzi, M., Wright, G., Gibellini, F., Nakayama, K., Liu, H., Rosenwald, A., Muller-Hermelink, H. K., Ott, G., et al. (2007) · Blood · doi:10.1182/blood-2006-08-039859 · Cited by 252
Misra, R. N., Xiao, H.-Y., Kim, K. S., Lu, S., Han, W.-C., Barbosa, S. A., Hunt, J. T., Rawlins, D. B., Shan, W., Ahmed, S. Z., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0305568 · Cited by 252
Patel, V, Senderowicz, A. M., Pinto, D., Igishi, T., Raffeld, M., Quintanilla-Martinez, L., Ensley, J. F., Sausville, E. A., & Gutkind, J. S. (1998) · Journal of Clinical Investigation · doi:10.1172/jci3661 · Cited by 246
Development of Cell-Cycle Inhibitors for Cancer Therapy
Dickson, M. A., & Schwartz, G. K. (2009) · Current Oncology · doi:10.3747/co.v16i2.428 · Cited by 246
Molecular pathways: CDK4 inhibitors for cancer therapy
Dickson, M. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1551 · Cited by 245
The CDK inhibitors in cancer research and therapy
Cicenas, J., & Valius, M. (2011) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-011-1039-4 · Cited by 243
Havlíček, L., Hanuš, J., Veselý, J., Leclerc, S., Meijer, L., Shaw, G., & Strnad, M. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm960666x · Cited by 243
Cyclin D1 in non-small cell lung cancer: A key driver of malignant transformation
Gautschi, O., Ratschiller, D., Gugger, M., Betticher, D. C., & Heighway, J. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2006.09.024 · Cited by 243
Chemical Genetics: Where Genetics and Pharmacology Meet
Knight, Z. A., & Shokat, K. M. (2007) · Cell · doi:10.1016/j.cell.2007.01.021 · Cited by 243
The cdk-activating kinase (CAK): from yeast to mammals
Kaldis, P. (1999) · Cellular and Molecular Life Sciences CMLS · doi:10.1007/s000180050290 · Cited by 242
Aggarwal, P., Vaites, L. P., Kim, J. K., Mellert, H., Gurung, B., Nakagawa, H., Herlyn, M., Hua, X., Rustgi, A. K., McMahon, S. B., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.08.012 · Cited by 242
CDK inhibitors in cancer therapy: what is next?
Malumbres, M., Pevarello, P., Barbacid, M., & Bischoff, J. R. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.10.012 · Cited by 240
Structural basis of inhibition of CDK–cyclin complexes by INK4 inhibitors
Jeffrey, P. D., Tong, L., & Pavletich, N. P. (2000) · Genes & Development · doi:10.1101/gad.851100 · Cited by 239
Cdk5: a multifaceted kinase in neurodegenerative diseases
Cheung, Z. H., & Ip, N. Y. (2012) · Trends in Cell Biology · doi:10.1016/j.tcb.2011.11.003 · Cited by 233
WANG, S., & FISCHER, P. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.03.003 · Cited by 232
Iorns, E., Turner, N. C., Elliott, R., Syed, N., Garrone, O., Gasco, M., Tutt, A. N. J., Crook, T., Lord, C. J., & Ashworth, A. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.01.001 · Cited by 230
Baughn, L. B., Di Liberto, M., Wu, K., Toogood, P. L., Louie, T., Gottschalk, R., Niesvizky, R., Cho, H., Ely, S., Moore, M. A. S., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1098 · Cited by 225
Zaharevitz, D. W., Gussio, R., Leost, M., Senderowicz, A. M., Lahusen, T. J., Kunick, C., Meijer, L., & Sausville, E. A. (1999) · PubMed · Cited by 225
Morelli, X., Bourgeas, R., & Roche, P. (2011) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2011.05.024 · Cited by 223
Deregulation of cyclin E in breast cancer.
Keyomarsi, K., Conte, D., Toyofuku, W. M., & Fox, M. (1995) · PubMed · Cited by 222
Lin, T. S., Ruppert, A. S., Johnson, A. J., Fischer, B., Heerema, N. A., Andritsos, L. A., Blum, K. A., Flynn, J. M., Jones, J. A., Hu, W., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.6944 · Cited by 222
Butyrolactone I, a selective inhibitor of cdk2 and cdc2 kinase.
Kitagawa, M., Okabe, T., Ogino, H., et al. (1993) · PubMed · Cited by 221
Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor
Davies, T. G., Bentley, J., Arris, C. E., Boyle, F. T., Curtin, N. J., Endicott, J. A., Gibson, A. E., Golding, B. T., Griffin, R. J., Hardcastle, I. R., et al. (2002) · Nature Structural Biology · doi:10.1038/nsb842 · Cited by 219
Effects of Phosphorylation of Threonine 160 on Cyclin-dependent Kinase 2 Structure and Activity
Brown, N. R., Noble, M. E. M., Lawrie, A. M., Morris, M. C., Tunnah, P., Divita, G., Johnson, L. N., & Endicott, J. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.13.8746 · Cited by 217
Self-citationA census of mitotic cancer genes: new insights into tumor cell biology and cancer therapy
Perez de Castro, I., de Carcer, G., & Malumbres, M. (2006) · Carcinogenesis · doi:10.1093/carcin/bgm019 · Cited by 216
Arris, C. E., Boyle, F. T., Calvert, A. H., Curtin, N. J., Endicott, J. A., Garman, E. F., Gibson, A. E., Golding, B. T., Grant, S., Griffin, R. J., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990628o · Cited by 215
Tong, W.-G., Chen, R., Plunkett, W., Siegel, D., Sinha, R., Harvey, R. D., Badros, A. Z., Popplewell, L., Coutre, S., Fox, J. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.1347 · Cited by 215
Åkervall, J. A., Michalides, R. J. A. M., Mineta, H., Balm, A., Borg, Å., Dictor, M. R., Jin, Y., Loftus, B., Mertens, F., & Wennerberg, J. P. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970115)79:2<380::aid-cncr22>3.3.co;2-5 · Cited by 214
Physiological Relevance of Cell Cycle Kinases
Malumbres, M. (2011) · Physiological Reviews · doi:10.1152/physrev.00025.2010 · Cited by 213
Regulation of lipogenesis by cyclin-dependent kinase 8–mediated control of SREBP-1
Zhao, X., Feng, D., Wang, Q., Abdulla, A., Xie, X.-J., Zhou, J., Sun, Y., Yang, E. S., Liu, L.-P., Vaitheesvaran, B., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61462 · Cited by 213
Mendrzyk, F., Radlwimmer, B., Joos, S., Kokocinski, F., Benner, A., Stange, D. E., Neben, K., Fiegler, H., Carter, N. P., Reifenberger, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.8589 · Cited by 213
Wide spectrum of tumors in knock‐in mice carrying a Cdk4 protein insensitive to INK4 inhibitors
Sotillo, R., Dubus, P., Martn, J., de la Cueva, E., Ortega, S., Malumbres, M., & Barbacid, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.23.6637 · Cited by 208
Karst, A. M., Jones, P. M., Vena, N., Ligon, A. H., Liu, J. F., Hirsch, M. S., Etemadmoghadam, D., Bowtell, D. D. L., & Drapkin, R. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2247 · Cited by 208
Therapeutic peptides revisited
Latham, P. W. (1999) · Nature Biotechnology · doi:10.1038/11686 · Cited by 207
Li, J., Gaillard, F., Moreau, A., et al. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65399-0 · Cited by 207
Donnellan, R., & Chetty, R. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.8.773 · Cited by 206
Gompel, M., Leost, M., De Kier Joffe, E. B., Puricelli, L., Franco, L. H., Palermo, J., & Meijer, L. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.01.050 · Cited by 204
Haber, D. A., & Settleman, J. (2007) · Nature · doi:10.1038/446145a · Cited by 203
Nakayama, N., Nakayama, K., Shamima, Y., Ishikawa, M., Katagiri, A., Iida, K., & Miyazaki, K. (2010) · Cancer · doi:10.1002/cncr.24987 · Cited by 201
Fang, Z., Grütter, C., & Rauh, D. (2013) · ACS Chemical Biology · doi:10.1021/cb300663j · Cited by 197
Targeting cyclin B1 through peptide-based delivery of siRNA prevents tumour growth
Crombez, L., Morris, M. C., Dufort, S., Aldrian-Herrada, G., Nguyen, Q., Mc Master, G., Coll, J.-L., Heitz, F., & Divita, G. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp451 · Cited by 193
Self-citationRegulation of G1 cell-cycle progression by oncogenes and tumor suppressor genes
Ho, A. (2002) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(01)00263-5 · Cited by 192
König, A., Schwartz, G. K., Mohammad, R. M., Al-Katib, A., & Gabrilove, J. L. (1997) · Blood · doi:10.1182/blood.v90.11.4307 · Cited by 191
The crystal structure of cyclin A
Brown, N., Noble, M., Endicott, J., Garman, E., Wakatsuki, S., Mitchell, E., Rasmussen, B., Hunt, T., & Johnson, L. (1995) · Structure · doi:10.1016/s0969-2126(01)00259-3 · Cited by 191
Cen, L., Carlson, B. L., Schroeder, M. A., Ostrem, J. L., Kitange, G. J., Mladek, A. C., Fink, S. R., Decker, P. A., Wu, W., Kim, J.-S., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos114 · Cited by 189
A Cdk5 inhibitory peptide reduces tau hyperphosphorylation and apoptosis in neurons
Zheng, Y., Kesavapany, S., Gravell, M., Hamilton, R. S., Schubert, M., Amin, N., Albers, W., Grant, P., & Pant, H. C. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600441 · Cited by 189
Bu, B., Li, J., Davies, P., & Vincent, I. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-15-06515.2002 · Cited by 188
CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases
Bettayeb, K., Oumata, N., Echalier, A., Ferandin, Y., Endicott, J. A., Galons, H., & Meijer, L. (2008) · Oncogene · doi:10.1038/onc.2008.191 · Cited by 184
Ali, F., Hindley, C., McDowell, G., Deibler, R., Jones, A., Kirschner, M., Guillemot, F., & Philpott, A. (2011) · Development · doi:10.1242/dev.067900 · Cited by 181
Small Molecules as Inhibitors of Cyclin‐Dependent Kinases
Huwe, A., Mazitschek, R., & Giannis, A. (2003) · Angewandte Chemie International Edition · doi:10.1002/anie.200200540 · Cited by 181
Alkaloids from the antarctic sponge Kirkpatrickia varialosa.
Perry, N. B., Ettouati, L., Litaudon, M., Blunt, J. W., Munro, M. H. G., Parkin, S., & Hope, H. (1994) · Tetrahedron · doi:10.1016/s0040-4020(01)89673-3 · Cited by 176
Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases
Paruch, K., Dwyer, M. P., Alvarez, C., Brown, C., Chan, T.-Y., Doll, R. J., Keertikar, K., Knutson, C., McKittrick, B., Rivera, J., et al. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml100051d · Cited by 175
Costello, J., Plass, C., Arap, W., Chapman, V. M., Held, W. A., Berger, M. S., Huang, H., & Cavenee, W. K. (1997) · PubMed · Cited by 173
Squires, M. S., Feltell, R. E., Wallis, N. G., Lewis, E. J., Smith, D.-M., Cross, D. M., Lyons, J. F., & Thompson, N. T. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0890 · Cited by 171
Fåhraeus, R., Paramio, J. M., Ball, K. L., Laín, S., & Lane, D. P. (1996) · Current Biology · doi:10.1016/s0960-9822(02)00425-6 · Cited by 170
Emerging classes of protein–protein interaction inhibitors and new tools for their development
Pagliaro, L., Felding, J., Audouze, K., Nielsen, S. J., Terry, R. B., Krog-Jensen, C., & Butcher, S. (2004) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2004.06.006 · Cited by 168
Identification of mutations that disrupt phosphorylation-dependent nuclear export of cyclin D1
Benzeno, S., Lu, F., Guo, M., Barbash, O., Zhang, F., Herman, J. G., Klein, P. S., Rustgi, A. K., & Diehl, J. A. (2006) · Oncogene · doi:10.1038/sj.onc.1209644 · Cited by 167
CDK11 Complexes Promote Pre-mRNA Splicing
Hu, D., Mayeda, A., Trembley, J. H., Lahti, J. M., & Kidd, V. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210057200 · Cited by 166
Inhibition of Cyclin-Dependent Kinase 4 (Cdk4) by Fascaplysin, a Marine Natural Product
Soni, R., Muller, L., Furet, P., Schoepfer, J., Stephan, C., Zumstein-Mecker, S., Fretz, H., & Chaudhuri, B. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3349 · Cited by 166
Interfacial inhibition of macromolecular interactions: nature's paradigm for drug discovery
Pommier, Y., & Cherfils, J. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.01.008 · Cited by 165
An Unusual Member of the Cdk Family: Cdk5
Dhariwala, F. A., & Rajadhyaksha, M. S. (2008) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-007-9242-1 · Cited by 164
Feldmann, G., Mishra, A., Hong, S.-M., Bisht, S., Strock, C. J., Ball, D. W., Goggins, M., Maitra, A., & Nelkin, B. D. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1107 · Cited by 163
Strock, C. J., Park, J.-I., Nakakura, E. K., Bova, G. S., Isaacs, J. T., Ball, D. W., & Nelkin, B. D. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3048 · Cited by 163
Cyclin-dependent kinase inhibitors
Dai, Y. (2003) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(03)00079-1 · Cited by 163
Complexities in the development of cyclin-dependent kinase inhibitor drugs
Sausville, E. A. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02308-0 · Cited by 160
An, H.-X., Beckmann, M. W., Reifenberger, G., Bender, H. G., & Niederacher, D. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65257-1 · Cited by 160
Pyrido[2,3-d]pyrimidin-7-one Inhibitors of Cyclin-Dependent Kinases
Barvian, M. R., Boschelli, D. H., Cossrow, J., Dobrusin, E. M., Fattaey, A., Fritsch, A., Fry, D. W., Harvey, P., Keller, P. R., Garrett, M. D., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000271k · Cited by 157
Ball, K. L., Laín, S., Fåhræus, R., Smythe, C., & Lane, D. P. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00029-7 · Cited by 157
Cyclins and their partners: from a simple idea to complicated reality.
Hunt, T. (1991) · PubMed · Cited by 156
Wong, A. S. L., Lee, R. H. K., Cheung, A. Y., Yeung, P. K. K., Chung, S. K., Cheung, Z. H., & Ip, N. Y. (2011) · Nature Cell Biology · doi:10.1038/ncb2217 · Cited by 155
Corcoran, M., Mould, S., Orchard, J., Ibbotson, R., Chapman, R., Boright, A. P., Platt, C., Tsui, L.-C., Scherer, S. W., & Oscier, D. (1999) · Oncogene · doi:10.1038/sj.onc.1203033 · Cited by 153
Cited by
Matthews, H. K., Bertoli, C., & de Bruin, R. A. M. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00404-3 · Cited by 1,506
Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy
Alix-Panabières, C., & Pantel, K. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1483 · Cited by 1,394
A historical overview of protein kinases and their targeted small molecule inhibitors
Roskoski, R. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.07.010 · Cited by 526
Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2018.11.035 · Cited by 393
Chiangjong, W., Chutipongtanate, S., & Hongeng, S. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5099 · Cited by 388
Metadata
- Authors
- Peyressatre, M., Prével, C., Pellerano, M., & Morris, M.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2015-01-23
- Volume
- 7
- Issue
- 1
- Pages
- 179-237
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W2143238584
- Cited by
- 344
- References
- 405
- FWCI
- 10.14
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.